Christian Angermayer
As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.
Psygen and Filament Health, Canadian psychedelic companies, discuss the transformative potential of psychedelics for mental health, addressing manufacturing challenges and the development of standardized natural psychedelic medicines.
Benjamin Lightburn, Daniel “Danny” Motyka
Psychedelic businesses have rapidly emerged on American and Canadian exchanges, creating a multibillion dollar market. Industry insiders discuss challenges and predictions for psychedelic public companies.
Patrick Trucchio, Florian Brand, George Tziras, Tim Chang
Hardman provides a quick overview of the emerging psychedelic sector, covering financial, research, and policy landscapes with data visuals. He also explores unanswered questions about the sector's future.
Josh Hardman
Panel on regulatory obstacles in psychedelic therapy research: Leaders from the industry discuss challenges with policymakers and predict future developments in the field.
Tadeusz Hawrot, Natasia Poinsatte, Nicole Howell
Funding for psychedelic medicine is evolving, with a rise in commercial capital alongside philanthropic support. Balancing financial interests with equitable access and learning from scaling challenges are key considerations.
Henry Elkus
Dr. Bennett explores the expanding field of ketamine treatment, covering current trends, controversies, and potential topics like enantiomers, mail order platforms, provider training, economics, and FDA approval challenges.
Thirty-eight states and DC allow marijuana use, fueling a $13b industry. Psychedelic entrepreneurs seek lessons from cannabis market, noting similarities and differences for future growth.
Steve DeAngelo, Amanda Reiman, Troy Dayton
Elliot Cohen (Pillpack, Amazon) and Protik Basu (World Bank, UN, Helena) share insights on healthcare delivery, psychedelics industry, scaling challenges, and technology's role in patient care.
Andrew “Mo” Septimus, Protik Basu, Elliot Cohen
Commander Gunn, a USPHS officer and FDA Investigator, specializes in international inspections of drug, biologic, and device trial sponsors and study sites. With 13 years of experience, he previously held
Commander Gene Gunn
© 1986 – 2025 Multidisciplinary Association for Psychedelic Studies. All Rights Reserved.
3141 Stevens Creek Blvd #40563, San Jose, CA 95117.
Mailing: MAPS P.O. Box 103004 Pasadena, CA 91189-3004.